Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 232870, 11 pages
http://dx.doi.org/10.1155/2014/232870
Review Article

Brd4 and HEXIM1: Multiple Roles in P-TEFb Regulation and Cancer

1State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian 361005, China
2Department of Orthopaedic Surgery, Lawrence J. Ellison Musculoskeletal Research Center, University of California at Davis Medical Center, Sacramento, CA 95817, USA
3Expression Engineering Group, Bioprocessing Technology Institute, A*STAR (Agency for Science, Technology and Research), 20 Biopolis Way, No. 06-01, Singapore 138668
4Department of Microbiology, National University of Singapore, Block MD4, 5 Science Drive 2, Singapore 117597

Received 6 November 2013; Accepted 19 December 2013; Published 29 January 2014

Academic Editor: Kaei Nasu

Copyright © 2014 Ruichuan Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. F. Marshall and D. H. Price, “Purification of P-TEFb, a transcription factor required for the transition into productive elongation,” The Journal of Biological Chemistry, vol. 270, no. 21, pp. 12335–12338, 1995. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Henriques, D. A. Gilchrist, S. Nechaev et al., “Stable pausing by RNA polymerase II provides an opportunity to target and integrate regulatory signals,” Molecular Cell, vol. 52, no. 4, pp. 517–528, 2013. View at Google Scholar
  3. T. Wada, T. Takagi, Y. Yamaguchi, D. Watanabe, and H. Handa, “Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II-dependent transcription in vitro,” The EMBO Journal, vol. 17, no. 24, pp. 7395–7403, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Yamaguchi, T. Takagi, T. Wada et al., “NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation,” Cell, vol. 97, no. 1, pp. 41–51, 1999. View at Google Scholar · View at Scopus
  5. B. Cheng, T. Li, P. B. Rahl et al., “Functional association of gdown1 with RNA polymerase II poised on human genes,” Molecular Cell, vol. 45, no. 1, pp. 38–50, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Fujinaga, D. Irwin, Y. Huang, R. Taube, T. Kurosu, and B. M. Peterlin, “Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element,” Molecular and Cellular Biology, vol. 24, no. 2, pp. 787–795, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Ivanov, Y. T. Kwak, J. Guo, and R. B. Gaynor, “Domains in the SPT5 protein that modulate its transcriptional regulatory properties,” Molecular and Cellular Biology, vol. 20, no. 9, pp. 2970–2983, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. D. C. Hargreaves, T. Horng, and R. Medzhitov, “Control of inducible gene expression by signal-dependent transcriptional elongation,” Cell, vol. 138, no. 1, pp. 129–145, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Zippo, R. Serafini, M. Rocchigiani, S. Pennacchini, A. Krepelova, and S. Oliviero, “Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation,” Cell, vol. 138, no. 6, pp. 1122–1136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. S.-H. Chao, K. Fujinaga, J. E. Marion et al., “Flavopiridol inhibits P-TEFb and blocks HIV-1 replication,” The Journal of Biological Chemistry, vol. 275, no. 37, pp. 28345–28348, 2000. View at Google Scholar · View at Scopus
  11. S.-H. Chao and D. H. Price, “Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo,” The Journal of Biological Chemistry, vol. 276, no. 34, pp. 31793–31799, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. M. G. Guenther, S. S. Levine, L. A. Boyer, R. Jaenisch, and R. A. Young, “A chromatin landmark and transcription initiation at most promoters in human cells,” Cell, vol. 130, no. 1, pp. 77–88, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Zeitlinger, A. Stark, M. Kellis et al., “RNA polymerase stalling at developmental control genes in the Drosophila melanogaster embryo,” Nature Genetics, vol. 39, no. 12, pp. 1512–1516, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. G. W. Muse, D. A. Gilchrist, S. Nechaev et al., “RNA polymerase is poised for activation across the genome,” Nature Genetics, vol. 39, no. 12, pp. 1507–1511, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Kwak, N. J. Fuda, L. J. Core, and J. T. Lis, “Precise maps of RNA polymerase reveal how promoters direct initiation and pausing,” Science, vol. 339, no. 6122, pp. 950–953, 2013. View at Google Scholar
  16. L. J. Core, J. J. Waterfall, D. A. Gilchrist et al., “Defining the status of RNA polymerase at promoters,” Cell Reports, vol. 2, no. 4, pp. 1025–1035, 2012. View at Google Scholar
  17. M. F. Laspia, A. P. Rice, and M. B. Mathews, “HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation,” Cell, vol. 59, no. 2, pp. 283–292, 1989. View at Google Scholar · View at Scopus
  18. J. Wimmer, K. Fujinaga, R. Taube et al., “Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b,” Virology, vol. 255, no. 1, pp. 182–189, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. M. E. Garber, P. Wei, V. N. KewalRamani et al., “The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein,” Genes and Development, vol. 12, no. 22, pp. 3512–3527, 1998. View at Google Scholar · View at Scopus
  20. D. Chen, Y. Fong, and Q. Zhou, “Specific interaction of Tat with the human but not rodent P-TEFb complex mediates the species-specific Tat activation of HIV-1 transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 6, pp. 2728–2733, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Peng, N. F. Marshall, and D. H. Price, “Identification of a cyclin subunit required for the function of Drosophila P-TEFb,” The Journal of Biological Chemistry, vol. 273, no. 22, pp. 13855–13860, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Wei, M. E. Garber, S.-M. Fang, W. H. Fischer, and K. A. Jones, “A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA,” Cell, vol. 92, no. 4, pp. 451–462, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Y. Shim, A. K. Walker, Y. Shi, and T. K. Blackwell, “CDK-9/cyclin T (P-TEFb) is required in two postinitiation pathways for transcription in the C. elegans embryo,” Genes and Development, vol. 16, no. 16, pp. 2135–2146, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Ni, B. E. Schwartz, J. Werner, J.-R. Suarez, and J. T. Lis, “Coordination of transcription, RNA processing, and surveillance by P-TEFb kinase on heat shock genes,” Molecular Cell, vol. 13, no. 1, pp. 55–65, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Bartkowiak, P. Liu, H. P. Phatnani et al., “CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1,” Genes and Development, vol. 24, no. 20, pp. 2303–2316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. S. M. Shore, S. A. Byers, W. Maury, and D. H. Price, “Identification of a novel isoform of Cdk9,” Gene, vol. 307, no. 1-2, pp. 175–182, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Peng, Y. Zhu, J. T. Milton, and D. H. Price, “Identification of multiple cyclin subunits of human P-TEFb,” Genes and Development, vol. 12, no. 5, pp. 755–762, 1998. View at Google Scholar · View at Scopus
  28. T.-J. Fu, J. Peng, G. Lee, D. H. Price, and O. Flores, “Cyclin K functions as a CDK9 regulatory subunit and participates in RNA polymerase II transcription,” The Journal of Biological Chemistry, vol. 274, no. 49, pp. 34527–34530, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. J. H. N. Yik, R. Chen, R. Nishimura, J. L. Jennings, A. J. Link, and Q. Zhou, “Inhibition of P-TEFb (CDK9/cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA,” Molecular Cell, vol. 12, no. 4, pp. 971–982, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. A. A. Michels, V. T. Nguyen, A. Fraldi et al., “MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcription-dependent manner,” Molecular and Cellular Biology, vol. 23, no. 14, pp. 4859–4869, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Jeronimo, D. Forget, A. Bouchard et al., “Systematic analysis of the protein interaction network for the human transcription machinery reveals the identity of the 7SK capping enzyme,” Molecular Cell, vol. 27, no. 2, pp. 262–274, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. B. J. Krueger, C. Jeronimo, B. B. Roy et al., “LARP7 is a stable component of the 7SK snRNP while P-TEFb, HEXIM1 and hnRNP A1 are reversibly associated,” Nucleic Acids Research, vol. 36, no. 7, pp. 2219–2229, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. A. A. Michels, A. Fraldi, Q. Li et al., “Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor,” The EMBO Journal, vol. 23, no. 13, pp. 2608–2619, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Barboric, J. Kohoutek, J. P. Price, D. Blazek, D. H. Price, and B. M. Peterlin, “Interplay between 7SK snRNA and oppositely charged regions in HEXIM1 direct the inhibition of P-TEFb,” The EMBO Journal, vol. 24, no. 24, pp. 4291–4303, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. Yang, J. H. N. Yik, R. Chen et al., “Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4,” Molecular Cell, vol. 19, no. 4, pp. 535–545, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. M. K. Jang, K. Mochizuki, M. Zhou, H.-S. Jeong, J. N. Brady, and K. Ozato, “The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription,” Molecular Cell, vol. 19, no. 4, pp. 523–534, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. Q. Zhou and J. H. N. Yik, “The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation,” Microbiology and Molecular Biology Reviews, vol. 70, no. 3, pp. 646–659, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Dey, S.-H. Chao, and D. P. Lane, “HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy,” Cell Cycle, vol. 6, no. 15, pp. 1856–1863, 2007. View at Google Scholar · View at Scopus
  39. B. D. Strahl and C. D. Allis, “The language of covalent histone modifications,” Nature, vol. 403, no. 6765, pp. 41–45, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Sanchez and M.-M. Zhou, “The role of human bromodomains in chromatin biology and gene transcription,” Current Opinion in Drug Discovery and Development, vol. 12, no. 5, pp. 659–665, 2009. View at Google Scholar · View at Scopus
  41. P. Filippakopoulos, S. Picaud, M. Mangos et al., “Histone recognition and large-scale structural analysis of the human bromodomain family,” Cell, vol. 149, no. 1, pp. 214–231, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Muller, P. Filippakopoulos, and S. Knapp, “Bromodomains as therapeutic targets,” Expert Reviews in Molecular Medicine, vol. 13, p. e29, 2011. View at Google Scholar · View at Scopus
  43. C. M. Chiang, “Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4,” F1000 Biology Reports, vol. 1, p. 98, 2009. View at Google Scholar
  44. S. Rahman, M. E. Sowa, M. Ottinger et al., “The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3,” Molecular and Cellular Biology, vol. 31, no. 13, pp. 2641–2652, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Dey, F. Chitsaz, A. Abbasi, T. Misteli, and K. Ozato, “The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 8758–8763, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Dey, J. Ellenberg, A. Farina et al., “A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G2-to-M transition,” Molecular and Cellular Biology, vol. 20, no. 17, pp. 6537–6549, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Mochizuki, A. Nishiyama, M. K. Jang et al., “The bromodomain protein Brd4 stimulates g1 gene transcription and promotes progression to S phase,” The Journal of Biological Chemistry, vol. 283, no. 14, pp. 9040–9048, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. Z. Yang, N. He, and Q. Zhou, “Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G 1 gene expression and cell cycle progression,” Molecular and Cellular Biology, vol. 28, no. 3, pp. 967–976, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Dey, A. Nishiyama, T. Karpova, J. McNally, and K. Ozato, “Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription,” Molecular Biology of the Cell, vol. 20, no. 23, pp. 4899–4909, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Zhao, T. Nakamura, Y. Fu, Z. Lazar, and D. L. Spector, “Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re-activation,” Nature Cell Biology, vol. 13, no. 11, pp. 1295–1304, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. B. N. Devaiah and D. S. Singer, “Two faces of BRD4: mitotic bookmark and transcriptional lynchpin,” Transcription, vol. 4, no. 1, pp. 13–17, 2012. View at Google Scholar
  52. P. Voigt and D. Reinberg, “BRD4 jump-starts transcription after mitotic silencing,” Genome Biology, vol. 12, no. 11, article 133, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Wang, Q. Li, C. M. Helfer, J. Jiao, and J. You, “Bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure,” The Journal of Biological Chemistry, vol. 287, no. 14, pp. 10738–10752, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. J. You, J. L. Croyle, A. Nishimura, K. Ozato, and P. M. Howley, “Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes,” Cell, vol. 117, no. 3, pp. 349–360, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. D. A. Bisgrove, T. Mahmoudi, P. Henklein, and E. Verdin, “Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 34, pp. 13690–13695, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Nechaev and K. Adelman, “Pol II waiting in the starting gates: regulating the transition from transcription initiation into productive elongation,” Biochimica et Biophysica Acta, vol. 1809, no. 1, pp. 34–45, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. Q. Zhou, T. Li, and D. H. Price, “RNA polymerase II elongation control,” Annual Review of Biochemistry, vol. 81, pp. 119–143, 2012. View at Google Scholar
  58. J. Guo and D. H. Price, “RNA polymerase II transcription elongation control,” Chemical Reviews, vol. 113, no. 11, pp. 8583–8603, 2013. View at Google Scholar
  59. G. Diribarne and O. Bensaude, “7SK RNA, a non-coding RNA regulating P-TEFb, a general transcription factor,” RNA Biology, vol. 6, no. 2, pp. 122–128, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Xue, Z. Yang, R. Chen, and Q. Zhou, “A capping-independent function of MePCE in stabilizing 7SK snRNA and facilitating the assembly of 7SK snRNP,” Nucleic Acids Research, vol. 38, no. 2, pp. 360–369, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. R. Chen, M. Liu, H. Li et al., “PP2B and PP1α cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling,” Genes and Development, vol. 22, no. 10, pp. 1356–1368, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. X. Contreras, M. Barboric, T. Lenasi, and B. M. Peterlin, “HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription,” PLoS Pathogens, vol. 3, no. 10, pp. 1459–1469, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Fujinaga, M. Barboric, Q. Li, Z. Luo, D. H. Price, and B. M. Peterlin, “PKC phosphorylates HEXIM1 and regulates P-TEFb activity,” Nucleic Acids Research, vol. 40, no. 18, pp. 9160–9170, 2012. View at Google Scholar
  64. N. Ai, X. Hu, F. Ding et al., “Signal-induced Brd4 release from chromatin is essential for its role transition from chromatin targeting to transcriptional regulation,” Nucleic Acids Research, vol. 39, no. 22, pp. 9592–9604, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. S. S. Gupta, T. Maetzig, G. N. Maertens et al., “Bromo and ET domain (BET) chromatin regulators serve as co-factors for murine leukemia virus integration,” Journal of Virology, 2013. View at Publisher · View at Google Scholar
  66. A. Sharma, R. C. Larue, M. R. Plumb et al., “BET proteins promote efficient murine leukemia virus integration at transcription start sites,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 29, pp. 12036–12041, 2013. View at Google Scholar
  67. D. M. Margolis and D. J. Hazuda, “Combined approaches for HIV cure,” Current Opinion in HIV and AIDS, vol. 8, no. 3, pp. 230–235, 2013. View at Google Scholar
  68. J. Karn, “A new BET on the control of HIV latency,” Cell Cycle, vol. 12, no. 4, pp. 545–546, 2013. View at Google Scholar
  69. M. Zhou, K. Huang, K.-J. Jung et al., “Bromodomain protein Brd4 regulates human immunodeficiency virus transcription through phosphorylation of CDK9 at threonine 29,” Journal of Virology, vol. 83, no. 2, pp. 1036–1044, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. R. Chen, M. Liu, K. Zhang, and Q. Zhou, “Isolation and functional characterization of P-TEFb-associated factors that control general and HIV-1 transcriptional elongation,” Methods, vol. 53, no. 1, pp. 85–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. G. Zhang, R. Liu, Y. Zhong et al., “Down-regulation of NF-kappaB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition,” The Journal of Biological Chemistry, vol. 287, no. 34, pp. 28840–28851, 2012. View at Google Scholar
  72. B. Huang, X.-D. Yang, M.-M. Zhou, K. Ozato, and L.-F. Chen, “Brd4 coactivates transcriptional activation of NF-κB via specific binding to acetylated RelA,” Molecular and Cellular Biology, vol. 29, no. 5, pp. 1375–1387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. P. Anand, J. D. Brown, C. Y. Lin et al., “BET bromodomains mediate transcriptional pause release in heart failure,” Cell, vol. 154, no. 3, pp. 569–582, 2013. View at Google Scholar
  74. J. I. Spiltoir, M. S. Stratton, M. A. Cavasin et al., “BET acetyl-lysine binding proteins control pathological cardiac hypertrophy,” Journal of Molecular and Cellular Cardiology, vol. 63, pp. 175–179, 2013. View at Google Scholar
  75. S. R. Floyd, M. E. Pacold, Q. Huang et al., “The bromodomain protein Brd4 insulates chromatin from DNA damage signalling,” Nature, vol. 498, no. 7453, pp. 246–250, 2013. View at Google Scholar
  76. S. Choi and C. J. Bakkenist, “Brd4 shields chromatin from ATM kinase signaling storms,” Science Signaling, vol. 6, no. 293, p. pe30, 2013. View at Google Scholar
  77. I. Barbieri, E. Cannizzaro, and M. A. Dawson, “Bromodomains as therapeutic targets in cancer,” Briefings in Functional Genomics, vol. 12, no. 3, pp. 219–230, 2013. View at Google Scholar
  78. A. C. Belkina and G. V. Denis, “BET domain co-regulators in obesity, inflammation and cancer,” Nature Reviews Cancer, vol. 12, no. 7, pp. 465–477, 2012. View at Google Scholar
  79. C. A. French, I. Miyoshi, I. Kubonishi, H. E. Grier, A. R. Perez-Atayde, and J. A. Fletcher, “BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma,” Cancer Research, vol. 63, no. 2, pp. 304–307, 2003. View at Google Scholar · View at Scopus
  80. C. A. French, I. Miyoshi, J. C. Aster et al., “BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19),” American Journal of Pathology, vol. 159, no. 6, pp. 1987–1992, 2001. View at Google Scholar · View at Scopus
  81. A. Polsani, K. A. Braithwaite, A. L. Alazraki, C. Abramowsky, and B. M. Shehata, “NUT midline carcinoma: an imaging case series and review of literature,” Pediatric Radiology, vol. 42, no. 2, pp. 205–210, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. C. A. French, “Pathogenesis of NUT midline carcinoma,” Annual Review of Pathology, vol. 7, pp. 247–265, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. C. A. French, “NUT midline carcinoma,” Cancer Genetics and Cytogenetics, vol. 203, no. 1, pp. 16–20, 2010. View at Google Scholar · View at Scopus
  84. J. Alsarraj and K. W. Hunter, “Bromodomain-Containing protein 4: a dynamic regulator of breast cancer metastasis through modulation of the extracellular matrix,” International Journal of Breast Cancer, vol. 2012, Article ID 670632, 7 pages, 2012. View at Publisher · View at Google Scholar
  85. J. Alsarraj, R. C. Walker, J. D. Webster et al., “Deletion of the proline-rich region of the murine metastasis susceptibility gene Brd4 promotes epithelial-to-mesenchymal transition- and stem cell-like conversion,” Cancer Research, vol. 71, no. 8, pp. 3121–3131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. Z. Zou, B. Huang, X. Wu et al., “Brd4 maintains constitutively active NF-kappaB in cancer cells by binding to acetylated RelA,” Oncogene, 2013. View at Publisher · View at Google Scholar
  87. G. A. Blobel, A. Kalota, P. V. Sanchez, and M. Carroll, “Short hairpin RNA screen reveals bromodomain proteins as novel targets in acute myeloid leukemia,” Cancer Cell, vol. 20, no. 3, pp. 287–288, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Zuber, J. Shi, E. Wang et al., “RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia,” Nature, vol. 478, no. 7370, pp. 524–528, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. M. A. Dawson, R. K. Prinjha, A. Dittmann et al., “Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia,” Nature, vol. 478, no. 7370, pp. 529–533, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. J. E. Delmore, G. C. Issa, M. E. Lemieux et al., “BET bromodomain inhibition as a therapeutic strategy to target c-Myc,” Cell, vol. 146, no. 6, pp. 904–917, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. J. A. Mertz, A. R. Conery, B. M. Bryant et al., “Targeting MYC dependence in cancer by inhibiting BET bromodomains,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 40, pp. 16669–16674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. M. F. Segura, B. Fontanals-Cirera, A. Gaziel-Sovran et al., “BRD4 sustains proliferation and represents a new target for epigenetic therapy in melanoma,” Cancer Research, vol. 73, no. 20, pp. 6264–6276, 2013. View at Google Scholar
  93. R. M. Rodriguez, C. Huidobro, R. G. Urdinguio et al., “Aberrant epigenetic regulation of bromodomain Brd4 in human colon cancer,” Journal of Molecular Medicine, vol. 90, no. 5, pp. 587–595, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. J. Loven, H. A. Hoke, C. Y. Lin et al., “Selective inhibition of tumor oncogenes by disruption of super-enhancers,” Cell, vol. 153, no. 2, pp. 320–334, 2013. View at Google Scholar
  95. S. Khochbin, “When are the BET factors the most sensitive to bromodomain inhibitors?” Transcription, vol. 4, no. 2, pp. 54–57, 2013. View at Google Scholar
  96. T. Banerjee and D. Chakravarti, “A peek into the complex realm of histone phosphorylation,” Molecular and Cellular Biology, vol. 31, no. 24, pp. 4858–4873, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. S. J. Nowak and V. G. Corces, “Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation,” Trends in Genetics, vol. 20, no. 4, pp. 214–220, 2004. View at Publisher · View at Google Scholar · View at Scopus
  98. D. Rossetto, N. Avvakumov, and J. Cote, “Histone phosphorylation: a chromatin modification involved in diverse nuclear events,” Epigenetics, vol. 7, no. 10, pp. 1098–1108, 2012. View at Google Scholar
  99. A. Sawicka and C. Seiser, “Histone H3 phosphorylation—a versatile chromatin modification for different occasions,” Biochimie, vol. 94, no. 11, pp. 2193–2201, 2012. View at Google Scholar
  100. L. C. Mahadevan, A. C. Willis, and M. J. Barratt, “Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors,” Cell, vol. 65, no. 5, pp. 775–783, 1991. View at Google Scholar · View at Scopus
  101. M. Kusuhara, K. Nagasaki, K. Kimura et al., “Cloning of hexamethylene-bis-acetamide-inducible transcript, HEXIM1, in human vascular smooth muscle cells,” Biomedical Research, vol. 20, no. 5, pp. 273–279, 1999. View at Google Scholar · View at Scopus
  102. S. Ghatpande, S. Goswami, S. Mathew et al., “Identification of a novel cardiac lineage-associated protein(cCLP-1): a candidate regulator of cardiogenesis,” Developmental Biology, vol. 208, no. 1, pp. 210–221, 1999. View at Publisher · View at Google Scholar · View at Scopus
  103. Q. J. Lew, K. L. Chu, Y. L. Chia, N. Cheong, and S. H. Chao, “HEXIM1, a New Player in the p53 Pathway,” Cancers, vol. 5, pp. 838–856, 2013. View at Google Scholar
  104. B. M. Wittmann, N. Wang, and M. M. Montano, “Identification of a novel inhibitor of breast cell growth that is down-regulated by estrogens and decreased in breast tumors,” Cancer Research, vol. 63, no. 16, pp. 5151–5158, 2003. View at Google Scholar · View at Scopus
  105. E. Castro-Rivera, I. Samudio, and S. Safe, “Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements,” The Journal of Biological Chemistry, vol. 276, no. 33, pp. 30853–30861, 2001. View at Publisher · View at Google Scholar · View at Scopus
  106. Y. Shang, X. Hu, J. DiRenzo, M. A. Lazar, and M. Brown, “Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription,” Cell, vol. 103, no. 6, pp. 843–852, 2000. View at Google Scholar · View at Scopus
  107. S. Ali and R. C. Coombes, “Estrogen receptor alpha in human breast cancer: occurrence and significance,” Journal of Mammary Gland Biology and Neoplasia, vol. 5, no. 3, pp. 271–281, 2000. View at Publisher · View at Google Scholar · View at Scopus
  108. B. S. Katzenellenbogen and J. Frasor, “Therapeutic Targeting in the Estrogen Receptor Hormonal Pathway,” Seminars in Oncology, vol. 31, no. 1, supplement 3, pp. 28–38, 2004. View at Google Scholar · View at Scopus
  109. B. M. Wittmann, K. Fujinaga, H. Deng, N. Ogba, and M. M. Montano, “The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1,” Oncogene, vol. 24, no. 36, pp. 5576–5588, 2005. View at Publisher · View at Google Scholar · View at Scopus
  110. J. S. Lewis-Wambi and V. C. Jordan, “Treatment of postmenopausal breast cancer with selective estrogen receptor modulators (SERMs),” Breast Disease, vol. 24, no. 1, pp. 93–105, 2005. View at Google Scholar · View at Scopus
  111. W. Ketchart, N. Ogba, A. Kresak, J. M. Albert, J. J. Pink, and M. M. Montano, “HEXIM1 is a critical determinant of the response to tamoxifen,” Oncogene, vol. 30, no. 33, pp. 3563–3569, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. N. Ferrara, H.-P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  113. N. Ogba, Y. Q. Doughman, L. J. Chaplin et al., “HEXIM1 modulates vascular endothelial growth factor expression and function in breast epithelial cells and mammary gland,” Oncogene, vol. 29, no. 25, pp. 3639–3649, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. I. J. Yeh, N. Ogba, H. Bensigner, S. M. Welford, and M. M. Montano, “HEXIM1 downregulates Hypoxia Inducible Factor-1 alpha protein stability,” Biochemical Journal, vol. 456, pp. 195–204, 2013. View at Google Scholar
  115. J. Folkman, “Role of angiogenesis in tumor growth and metastasis,” Seminars in Oncology, vol. 29, no. 6, supplement 16, pp. 15–18, 2002. View at Google Scholar · View at Scopus
  116. W. Ketchart, K. M. Smith, T. Krupka et al., “Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis,” Oncogene, vol. 32, no. 33, pp. 3829–3839, 2013. View at Google Scholar
  117. M. Gurumurthy, C. H. Tan, R. Ng et al., “Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription,” Journal of Molecular Biology, vol. 378, no. 2, pp. 302–317, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. E. Colombo, J.-C. Marine, D. Danovi, B. Falini, and P. G. Pelicci, “Nucleophosmin regulates the stability and transcriptional activity of p53,” Nature Cell Biology, vol. 4, no. 7, pp. 529–533, 2002. View at Publisher · View at Google Scholar · View at Scopus
  119. J. D. Weber, L. J. Taylor, M. F. Roussel, C. J. Sherr, and D. Bar-Sagi, “Nucleolar Arf sequesters Mdm2 and activates p53,” Nature Cell Biology, vol. 1, no. 1, pp. 20–26, 1999. View at Google Scholar · View at Scopus
  120. T. Kamijo, F. Zindy, M. F. Roussel et al., “Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19(ARF),” Cell, vol. 91, no. 5, pp. 649–659, 1997. View at Google Scholar · View at Scopus
  121. S. Kurki, K. Peltonen, L. Latonen et al., “Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation,” Cancer Cell, vol. 5, no. 5, pp. 465–475, 2004. View at Publisher · View at Google Scholar · View at Scopus
  122. B. Falini, C. Mecucci, E. Tiacci et al., “Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype,” The New England Journal of Medicine, vol. 352, no. 3, pp. 254–266, 2005. View at Publisher · View at Google Scholar · View at Scopus
  123. M. Alcalay, E. Tiacci, R. Bergomas et al., “Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance,” Blood, vol. 106, no. 3, pp. 899–902, 2005. View at Publisher · View at Google Scholar · View at Scopus
  124. Q. J. Lew, C. H. Tan, M. Gurumurthy et al., “NPMc+ AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anti-cancer compounds,” Cell Cycle, vol. 10, no. 12, pp. 1978–1987, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. A. J. Levine, “p53, the cellular gatekeeper for growth and division,” Cell, vol. 88, no. 3, pp. 323–331, 1997. View at Publisher · View at Google Scholar · View at Scopus
  126. R. Honda, H. Tanaka, and H. Yasuda, “Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53,” FEBS Letters, vol. 420, no. 1, pp. 25–27, 1997. View at Publisher · View at Google Scholar · View at Scopus
  127. M. S. Rodriguez, J. M. P. Desterro, S. Lain, D. P. Lane, and R. T. Hay, “Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation,” Molecular and Cellular Biology, vol. 20, no. 22, pp. 8458–8467, 2000. View at Publisher · View at Google Scholar · View at Scopus
  128. J. Lau, Q. J. Lew, G. Diribarne et al., “Ubiquitination of HEXIM1 by HDM2,” Cell Cycle, vol. 8, no. 14, pp. 2247–2254, 2009. View at Google Scholar · View at Scopus
  129. Q. J. Lew, Y. L. Chia, K. L. Chu et al., “Identification of HEXIM1 as a positive regulator of p53,” The Journal of Biological Chemistry, vol. 287, no. 43, pp. 36443–36454, 2012. View at Google Scholar